KALA BIO, Inc. (KALA)
(Delayed Data from NSDQ)
$7.55 USD
+0.07 (0.94%)
Updated Jul 15, 2024 03:54 PM ET
After-Market: $7.62 +0.07 (0.93%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KALA 7.55 +0.07(0.94%)
Will KALA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for KALA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KALA
Does KALA BIO (KALA) Have the Potential to Rally 152.83% as Wall Street Analysts Expect?
KALA BIO (KALA) Reports Q3 Loss, Misses Revenue Estimates
KALA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate
VYNE Gains on Preclinical Data for IPF Candidate
Madrigal (MDGL) Gains on NASH Treatment's Breakthrough Therapy Tag
Other News for KALA
Kala Pharmaceuticals to sell 1.197M shares at $5.85 in private placement
KALA BIO Announces $12,500,000 Private Placement
Kala Pharmaceuticals to sell 1.197M shares at $5.85 in private placement
KALA BIO to Present at Jefferies Global Healthcare Conference
Kala Pharmaceuticals price target lowered by $3 at H.C. Wainwright, here's why